Capromab Pendetide

Subscribe to Selected New Research on Capromab Pendetide

69 relevant articles (8 outcomes, 14 trials/studies) found for this Drug

Description: an (111)Indium-labeled IgG antibody against a prostate specific membrane antigen (PSMA); used in the evaluation of metastatic involvement in prostate cancer

Also Known As:

(III)In-CYT-356; CYT 356; CYT-356; Cytogen 356; Indium-111-CYT-356; Prostascint

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56522

Blood Proteins: 3890

Serum Globulins: 72

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

Capromab Pendetide: 69

Immunoproteins: 29

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

Capromab Pendetide: 69

Globulins: 299

Serum Globulins: 72

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

Capromab Pendetide: 69

Experts

1.	Haseman, M K: 3 articles (06/2002 - 04/2000)
2.	Manyak, Michael J: 2 articles (02/2008 - 08/2007)
3.	Rosenthal, S A: 2 articles (03/2001 - 04/2000)
4.	Polascik, T J: 2 articles (03/2001 - 04/2000)
5.	Haseman, Michael K: 1 article (08/2007)
6.	Rosenthal, Seth A: 1 article (08/2007)
7.	Kipper, Samuel L: 1 article (08/2007)
8.	Trout, J Richard: 1 article (08/2007)
9.	Mohammed, Aza A: 1 article (07/2007)
10.	Gujral, Sandeep S: 1 article (07/2007)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 02/01/2008 - "In long-term outcomes studies, fused (111)In capromab pendetide scans have delivered significant benefits for patient selection and improved treatment of prostate cancer." 01/01/2006 - "Investigations using radioimmunoscintigraphy with the radiolabeled 7E11 antibody capromab pendetide have significantly improved sensitivity for prostate cancer detection compared with standard cross-sectional imaging, based on tissue confirmation of pathologic results" 12/01/1998 - "CONCLUSIONS: The monoclonal antibody conjugate ProstaScint provides additional information in detection and localization of recurrent prostate cancer and would be helpful in the selection of patients for subsequent external beam radiation therapy." 04/01/1998 - "CONCLUSIONS: Capromab pendetide offers improved sensitivity in the detection of prostate cancer over other noninvasive techniques" 02/01/2008 - "Indium-111 capromab pendetide in the management of recurrent prostate cancer." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 11/01/1998 - "FDA Cytogen (Princeton, NJ) protocol studies using 111indium-labeled ProstaScint revealed correlation between areas of increased concentration in the prostate and biopsy-proven tumors in patients imaged pretherapy" 04/01/2007 - "CONCLUSIONS: Dose intensification to occult tumor targets without increasing rectal toxicity may be achieved using SPECT/CT ProstaScint" 03/01/2005 - "Image fusion, or coregistration, which is overlaying the functional images of capromab pendetide uptake on the anatomic CT or MRI images, provides a detailed map of cancer localization inside and outside the prostate gland" 07/01/2004 - "A novel technique for identifying areas of cancer within the prostate using ProstaScint images fused with pelvic computed tomography scans is also described" 01/01/2000 - "Disease stage was deemed more advanced in 3 of 13 (22%) patients with primary cancer and in 13 of 64 (20%) of those with recurrent disease based on ProstaScint findings when all other imaging tests were inconclusive" Get all the results and reference details, order at left...
3.	Neoplasm Metastasis (Metastasis) 12/20/2000 - "The distribution of positive ProstaScint results among the prostate/prostate bed, pelvic nodes, and extrapelvic nodes was nearly equal for all groups, except that a significantly greater percentage of extrapelvic metastases was found in the hormonal group (group 4)" 05/01/2005 - "The unique role of ProstaScint has been in evaluating patients with biochemical failure and in trying to discern metastasis before definitive therapy" 12/20/2000 - "No significant PSA-ProstaScint correlation was found in patients in group 4 for fossa recurrence, pelvic or extrapelvic metastases" 12/20/2000 - "Patients in group 3 also exhibited a weak PSA-ProstaScint association for detecting fossa recurrence (P = 0.038), and was insignificant for pelvic and extrapelvic metastases" 12/20/2000 - "RESULTS: The PSA level and ProstaScint scans positive in the prostate bed (P <0.001) and for pelvic metastases (P <0.001), but not for extrapelvic metastases, correlated significantly in group 1 patients" Get all the results and reference details, order at left...
4.	Adenocarcinoma 04/01/2001 - "CONCLUSION: The image fusion of the pelvic CT scan and ProstaScint scan helped identify foci of adenocarcinoma within the prostate that correlated well with biopsy results" 12/01/1998 - "PURPOSE: A study using monoclonal antibody ProstaScint was conducted to determine the role of radioscintigraphy for evaluation of patients with adenocarcinoma of the prostate" 07/01/2004 - "Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma." 10/01/2003 - "PURPOSE: To evaluate 4-year biochemical outcomes for patients with prostate adenocarcinoma who underwent radioimmunoguided (Prostascint) permanent prostate brachytherapy" 05/01/2008 - "PURPOSE: We evaluate the usefulness of pretreatment (111)Indium capromab pendetide (ProstaScint) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy" Get all the results and reference details, order at left...
5.	Carcinoma (Carcinomatosis) 09/01/1994 - "CONCLUSION: In this preliminary study, CYT-356 scanning appears to be a promising agent to accomplish specific staging of prostatic carcinoma." 12/20/2000 - "OBJECTIVES: To report the results of a retrospective study of 2290 ProstaScint scans of 2154 patients with prostate carcinoma done at 15 institutions" 08/15/1998 - "Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide." 04/01/1993 - "Although to date more agents have been used to image ovarian carcinoma than prostate cancer, research has been restimulated in prostate carcinoma imaging because of development of a promising MoAb conjugate, CYT-356" 06/01/1998 - "Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy." Get all the results and reference details, order at left...
10 Diseases and 69 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	human glutamate carboxypeptidase II
2.	Choline (Choline Chloride)
3.	Carbon Monoxide
4.	Capromab Pendetide
5.	Prostate-Specific Antigen (Semenogelase)
6.	Indium
7.	Immunoconjugates (Immunoconjugate)
8.	Yttrium
9.	Membrane Glycoproteins (Membrane Glycoprotein)
10.	Antibodies
16 Drugs and Important Bio-Agents and 35 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy)
2.	Lymph Node Excision (Lymph Node Dissection)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Brachytherapy
5.	Radioimmunotherapy
6 Therapies and Procedures and 19 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>